LifeSci Capital analyst Francois Brisebois assumed coverage of Avadel Pharmaceuticals (AVDL) with an Outperform rating and $21 price target The firm believes the company’s commercial investments are beginning to show benefits with improved persistency trends leading to a growing number of reimbursed patients on Lumryz. LifeSci sees further growth ahead and views Avadel’s idiopathic hypersomnia and low salt oxybate version efforts as upside to its price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals: Strong Sales Growth and Strategic Positioning Drive Buy Rating
- Avadel Pharmaceuticals initiated with an Equal Weight at Wells Fargo
- Avadel Pharmaceuticals price target raised to $20 from $13 at UBS
- Avadel Pharmaceuticals Reports Strong Earnings and Growth
- Avadel Pharmaceuticals price target raised to $18 from $16 at Deutsche Bank